Media Articles Related to Azilect (Rasagiline)
Virtually reality simplifies early diagnosis of multiple sclerosis and Parkinson's disease
Source: Multiple Sclerosis News From Medical News Today [2016.09.05]
Scientists from Tomsk Polytechnic University and Siberian State Medical University are developing an early diagnosis system for neurodegenerative disorders.
Experimental Test Detects Parkinson's Disease Earlier
Source: MedicineNet Creutzfeldt-Jakob Disease Specialty [2016.08.30]
Title: Experimental Test Detects Parkinson's Disease Earlier
Category: Health News
Created: 8/29/2016 12:00:00 AM
Last Editorial Review: 8/30/2016 12:00:00 AM
Source: MedicineNet Hoarseness Specialty [2016.08.09]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/9/2016 12:00:00 AM
Cancer Drug Shows Early Promise for Parkinson's Disease
Source: MedicineNet Tremor Specialty [2016.07.13]
Title: Cancer Drug Shows Early Promise for Parkinson's Disease
Category: Health News
Created: 7/12/2016 12:00:00 AM
Last Editorial Review: 7/13/2016 12:00:00 AM
Parkinson's Disease: Symptoms, Causes, Stages, Treatment
Source: MedicineNet rivastigmine Specialty [2016.06.01]
Title: Parkinson's Disease: Symptoms, Causes, Stages, Treatment
Created: 8/16/2011 6:25:00 PM
Last Editorial Review: 6/1/2016 12:00:00 AM
Published Studies Related to Azilect (Rasagiline)
Rasagiline treatment effects on parkinsonian tremor. 
Tremor is a common symptom of Parkinson's disease (PD). The underlying
pathophysiology of parkinsonian rest tremor is not well understood... These
data suggest that rasagiline used as monotherapy and as adjunctive therapy is
effective for reducing tremor severity in patients with PD.
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study... INTERPRETATION: These findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasagiline 1 mg per day early-start versus delayed-start group. The rate of UPDRS deterioration was less than was anticipated from previous studies and correlated with baseline severity. Understanding of the pattern of UPDRS deterioration is essential to assess disease modification. FUNDING: Teva Pharmaceutical Industries and H Lundbeck A/S. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...
Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension... Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.
The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive.The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
Clinical Trials Related to Azilect (Rasagiline)
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline [Completed]
Azilect´┐Ż (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China [Completed]
The rationale for conducting this study is to evaluate the efficacy, tolerability, and
safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD)
Chinese patients with motor fluctuations. Azilect« (Rasagiline) is indicated for the
treatment of idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with
levodopa) in patients with end of dose fluctuations.
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease [Completed]
Azilect + Antidepressant Chart Review [Completed]
To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients
receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline
without antidepressant medications and compared to PD patients receiving antidepressants,
but not rasagiline.
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
their first visit based on the drugs they are taking for their PD:
- Group 1 Patients using Azilect and no other therapy.
- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or
Reports of Suspected Azilect (Rasagiline) Side Effects
Drug Interaction (14),
Confusional State (8), more >>